CVS Caremark has released its annual report on drug trend and other issues. (CVS Trend Report) The trend information isn’t as useful as you might think, since you have to look very carefully at how it is calculated and from what groups and members. What would be really useful is a trend report on what is happening with what consumers actually pay for drugs–deductible, copays, coinsurance, full self-pay. But according to CVS, its book of business had an overall gross trend of one-tenth of a percent, with utilization and mix of drugs favorable, but unit pricing up. The non-specialty trend was actually down almost 4% but specialty was up over 18%, which is consistent with all the evidence indicating that spending increases are reasonable for most high-volume, chronic disease drugs, for which there often is a generic equivalent, but rising rapidly for specialty. The really bad news is that the pipeline is now heavily focused on specialty. Even large pharmas are successfully making the pivot from huge volume blockbuster brand-name drugs, to smaller population, but much higher priced, drugs. The report is themed around the “member” and how to improve the member’s experience. CVS highlights e-prescribing growth, more comprehensive and restrictive management of specialty drug channels and their enterprise digital strategy. Some specific disease areas were highlighted as well, largely for introduction of new drugs and the potential for higher spending. These included hepatitis C and multiple sclerosis. Looking forward, CVS projects about 1-5% spending growth in 2013, 2-7% in 2-14, 4-9% in 2015 and 5-10% in 2016, largely driven by specialty drugs and by provisions in the reform act. Not a pretty picture and one that should add to overall spending increase concerns, as drugs had been one of the slower growth areas in the last few years.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
November 4 Debt Auction
November 4, 2024
November 4 Debt Auction
Another disappointing US debt auction.
Commentary
The Party of the Rich and Why the Rich Don’t Pay Their Fair Share
November 4, 2024
The Party of the Rich and Why the Rich Don’t Pay Their Fair Share
Democrats are the party of the rich, they are owned by the rich, especially in…
Commentary
Thank God It Will All Be Over Soon
November 2, 2024
Thank God It Will All Be Over Soon
Our political process is driving us all crazy.